MX382864B - Formulaciones de anticuerpos cristalinos. - Google Patents

Formulaciones de anticuerpos cristalinos.

Info

Publication number
MX382864B
MX382864B MX2017000526A MX2017000526A MX382864B MX 382864 B MX382864 B MX 382864B MX 2017000526 A MX2017000526 A MX 2017000526A MX 2017000526 A MX2017000526 A MX 2017000526A MX 382864 B MX382864 B MX 382864B
Authority
MX
Mexico
Prior art keywords
antibody formulations
crystalline antibody
crystalline
formulations
antibody crystals
Prior art date
Application number
MX2017000526A
Other languages
English (en)
Other versions
MX2017000526A (es
Inventor
Christi L Clogston
Timothy David Osslund
Twinkle R Christian
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2017000526A publication Critical patent/MX2017000526A/es
Publication of MX382864B publication Critical patent/MX382864B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un cristal caracterizado porque consiste en un anticuerpo IgG anti-PCSK9 que comprende una región variable de cadena ligera que tienen las secuencia de aminoácidos establecida en SEQ ID NO: 9 o SEQ ID NO: 11 y una región variable de cadena pesad que comprende la secuencia de aminoácidos establecida en SEQ ID NO; 5 o SEQ ID NO: 7.
MX2017000526A 2014-07-14 2015-07-13 Formulaciones de anticuerpos cristalinos. MX382864B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462024399P 2014-07-14 2014-07-14
PCT/US2015/040211 WO2016010924A1 (en) 2014-07-14 2015-07-13 Crystalline antibody formulations

Publications (2)

Publication Number Publication Date
MX2017000526A MX2017000526A (es) 2017-08-02
MX382864B true MX382864B (es) 2025-03-13

Family

ID=53716611

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017000526A MX382864B (es) 2014-07-14 2015-07-13 Formulaciones de anticuerpos cristalinos.
MX2021006003A MX2021006003A (es) 2014-07-14 2017-01-12 Formulaciones de anticuerpos cristalinos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021006003A MX2021006003A (es) 2014-07-14 2017-01-12 Formulaciones de anticuerpos cristalinos.

Country Status (7)

Country Link
US (2) US10611850B2 (es)
EP (2) EP3929218A1 (es)
JP (4) JP6783223B2 (es)
AU (3) AU2015289967A1 (es)
CA (1) CA2954773C (es)
MX (2) MX382864B (es)
WO (1) WO2016010924A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
EP2790681B9 (en) 2011-11-18 2023-07-26 Regeneron Pharmaceuticals, Inc. Method of manufacturing an extended release pharmaceutical formulation comprising polymer coated protein microparticles using spray-drying
JP6783223B2 (ja) * 2014-07-14 2020-11-11 アムジェン インコーポレイテッド 結晶性抗体製剤
MX2017000527A (es) 2014-07-14 2017-08-10 Amgen Inc Formulaciones de anticuerpos cristalinos.
CA3001346A1 (en) * 2015-10-16 2017-04-20 Regeneron Pharmaceuticals, Inc. Stable protein compositions
WO2019099427A1 (en) * 2017-11-14 2019-05-23 The University Of North Carolina At Chapel Hill Compositions and methods for stabilization of proteins
GB2584687B (en) * 2019-06-11 2023-08-23 Univ Newcastle Crystallisation of chemical molecules

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0766564A4 (en) 1994-06-24 1998-09-23 Immunex Corp SLOW RELEASE POLYPEPTIDES COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL CONDITIONS
IL112834A (en) 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
US6020004A (en) 1997-04-17 2000-02-01 Amgen Inc. Biodegradable microparticles for the sustained delivery of therapeutic drugs
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US6432449B1 (en) 1998-05-18 2002-08-13 Amgen Inc. Biodegradable sustained-release alginate gels
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6451346B1 (en) 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
JP4731793B2 (ja) 2000-12-28 2011-07-27 アルセア テクノロジーズ インコーポレイテッド 抗体全体またはそのフラグメントの結晶、ならびにこの結晶を作製および使用するための方法
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
EA039663B1 (ru) * 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
MX2017000527A (es) 2014-07-14 2017-08-10 Amgen Inc Formulaciones de anticuerpos cristalinos.
JP6783223B2 (ja) * 2014-07-14 2020-11-11 アムジェン インコーポレイテッド 結晶性抗体製剤

Also Published As

Publication number Publication date
JP6783223B2 (ja) 2020-11-11
US20170198058A1 (en) 2017-07-13
EP3169709B1 (en) 2021-05-12
JP2020169200A (ja) 2020-10-15
MX2021006003A (es) 2021-07-06
US20200299410A1 (en) 2020-09-24
AU2021201409A1 (en) 2021-03-25
JP2018141004A (ja) 2018-09-13
MX2017000526A (es) 2017-08-02
CA2954773C (en) 2023-10-03
AU2024205016A1 (en) 2024-08-15
CA2954773A1 (en) 2016-01-21
US11773184B2 (en) 2023-10-03
AU2015289967A1 (en) 2017-02-02
JP2023055977A (ja) 2023-04-18
EP3929218A1 (en) 2021-12-29
JP7264853B2 (ja) 2023-04-25
JP2017525679A (ja) 2017-09-07
EP3169709A1 (en) 2017-05-24
WO2016010924A1 (en) 2016-01-21
US10611850B2 (en) 2020-04-07

Similar Documents

Publication Publication Date Title
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
MA40579A (fr) Anticorps anti-cll-1 et immunoconjugués
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
CL2016001871A1 (es) Anticuerpos humanos para pd-1
MX374788B (es) Anticuerpos anti-tim3 y metodos de uso.
GEAP202114450A (en) Anti-tigit antibodies
GEAP202114453A (en) Anti-lag3 antibodies and antigen-binding fragments
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201691991A1 (ru) Мультиспецифические антитела
MX2021008376A (es) Cultivo, produccion, procesamiento y uso de cannabis de especialidad.
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
MX2017000527A (es) Formulaciones de anticuerpos cristalinos.
MX2021006003A (es) Formulaciones de anticuerpos cristalinos.
MX377774B (es) Formulaciones de proteinas.
EA201691367A1 (ru) Кристаллические формы дималеата афатиниба
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
MX2019010640A (es) Formas cristalinas de acido obeticolico.
MX2016004573A (es) Inhibidores de nsp4 y metodos de uso.
EA201691203A1 (ru) Твёрдые формы тенофовира
MX2015010789A (es) Anticuerpos anti-pcsm.
UA114708U (uk) Тяговий привід електробуса
TWD175566S (zh) 雪鏡
TWD173435S (zh) 土除
UY37009A (es) Formulaciones granuladas de giberelina